Testing Mosunetuzumab Alone, With Zanubrutinib, or With Polatuzumab Vedotin for Treating Marginal Zone Lymphoma That Came Back or Didn't Get Better With Treatment
Public ClinicalTrials.gov record NCT07638722. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
MOZART MZL: A Randomized Phase II Study Evaluating Mosunetuzumab Alone and in Combination With Either Zanubrutinib or Polatuzumab Vedotin for the Treatment of Patients With Relapsed/Refractory Marginal Zone Lymphoma
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
This phase II trial compares the effect of mosunetuzumab alone to mosunetuzumab with zanubrutinib or polatuzumab vedotin in patients with marginal zone lymphoma that has come back after a period of improvement (relapsed) or that does not respond to treatment (refractory). Mosunetuzumab is a monoclonal antibody that may interfere with the ability of cancer cells to grow and spread. A monoclonal antibody is a type of protein that can bind to certain targets in the body, such as molecules that cause the body to make an immune response (antigens). Zanubrutinib is in a class of medications called kinase inhibitors. It blocks a protein called BTK, which is present on B-cell (a type of white blood cells) cancers such as marginal zone lymphoma at abnormal levels. This may help keep cancer cells from growing and spreading. Polatuzumab vedotin is a monoclonal antibody, called polatuzumab, linked to a drug, called monomethyl auristatin E. Polatuzumab is a form of targeted therapy because it attaches to specific molecules (receptors) on the surface of cancer cells, known as CD79B receptors, and delivers monomethyl auristatin E to kill them. Giving mosunetuzumab alone or with zanubrutinib or polatuzumab vedotin may work well for treating relapsed or refractory marginal zone lymphoma.
Study identification
- NCT ID
- NCT07638722
- Recruitment status
- Not yet recruiting
- Study type
- Interventional
- Phase
- Phase 2
- Enrollment
- 138 participants
Conditions and interventions
Conditions
- Recurrent Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue
- Recurrent Nodal Marginal Zone Lymphoma
- Recurrent Splenic Marginal Zone Lymphoma
- Refractory Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue
- Refractory Nodal Marginal Zone Lymphoma
- Refractory Splenic Marginal Zone Lymphoma
Interventions
- Biospecimen Collection Procedure
- Bone Marrow Biopsy Procedure
- Computed Tomography Procedure
- Mosunetuzumab Biological
- Polatuzumab Vedotin Drug
- Positron Emission Tomography Procedure
- Survey Administration Other
- Zanubrutinib Drug
Procedure · Biological · Drug + 1 more
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Oct 3, 2026 (Estimated)
- Primary completion
- Apr 3, 2034 (Estimated)
- Completion
- Apr 3, 2035 (Estimated)
- Last update posted
- Oct 13, 2026
2026 – 2035
United States locations
- U.S. sites
- 14
- U.S. states
- 5
- U.S. cities
- 13
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Helen F Graham Cancer Center | Newark | Delaware | 19713 | — |
| Medical Oncology Hematology Consultants PA | Newark | Delaware | 19713 | — |
| Kootenai Health - Coeur d'Alene | Coeur d'Alene | Idaho | 83814 | — |
| Kootenai Clinic Cancer Services - Post Falls | Post Falls | Idaho | 83854 | — |
| Kootenai Clinic Cancer Services - Sandpoint | Sandpoint | Idaho | 83864 | — |
| Trinity Health IHA Medical Group Hematology Oncology - Brighton | Brighton | Michigan | 48114 | — |
| Trinity Health IHA Medical Group Hematology Oncology - Canton | Canton | Michigan | 48188 | — |
| Trinity Health IHA Medical Group Hematology Oncology - Chelsea Hospital | Chelsea | Michigan | 48118 | — |
| Trinity Health Saint Mary Mercy Livonia Hospital | Livonia | Michigan | 48154 | — |
| Trinity Health Saint Joseph Mercy Oakland Hospital | Pontiac | Michigan | 48341 | — |
| Trinity Health IHA Medical Group Hematology Oncology Ann Arbor Campus | Ypsilanti | Michigan | 48197 | — |
| Billings Clinic Cancer Center | Billings | Montana | 59101 | — |
| Community Medical Center | Missoula | Montana | 59804 | — |
| Huntsman Cancer Institute/University of Utah | Salt Lake City | Utah | 84112 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT07638722, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Oct 13, 2026 · Synced Oct 13, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT07638722 live on ClinicalTrials.gov.